How it All Plays Out: Complementary Research on TrovaGene, Advaxis, NewLink Genetics, uniQure and Spark Therapeutics
NEW YORK, May 11, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including TrovaGene Inc. (NASDAQ: TROV), Advaxis Inc. (NASDAQ: ADXS), NewLink Genetics Corporation (NASDAQ: NLNK), uniQure N.V. (NASDAQ: QURE), and Spark Therapeutics Inc. (NASDAQ: ONCE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
TROV Research Report: ( http://get.analystsreview.com/pdf/?c=TrovaGene&d=11-May-2015&s=TROV ),
ADXS Research Report: ( http://get.analystsreview.com/pdf/?c=Advaxis&d=11-May-2015&s=ADXS ),
NLNK Research Report: ( http://get.analystsreview.com/pdf/?c=NewLink%20Genetics&d=11-May-2015&s=NLNK ),
QURE Research Report: ( http://get.analystsreview.com/pdf/?c=Uniqure&d=11-May-2015&s=QURE ),
ONCE Research Report: ( http://get.analystsreview.com/pdf/?c=Spark%20Therapeutics&d=11-May-2015&s=ONCE ).
============
--
Analyst Update: Stock Offeringsand Earnings
U.S. stocks advanced sharply on Friday, after stronger employment data for April suggested the US economy is gaining traction again. The Dow Jones Industrial Average rose 1.49%, to close at 18,191.11, the S&P 500 gained 1.35%, to 2,116.10, and the NASDAQ Composite finished the session at 5,003.55, up 1.17%. European stocks rallied on Friday, lifted by the UK election results, which showed the Conservative Party unexpectedly sweeping into power again. Germany's DAX 30 rose 2.65%, France's CAC 40 advanced 2.48%, and the London's FTSE 100 closed 2.32% higher on Friday. Meanwhile, Asian markets surged on Friday after losing ground in the last few days. The Shanghai Composite, Japan's Nikkei, and Hong Kong's Hang Seng all posted gains on Friday.
TrovaGene, Inc. (TrovaGene) on May 5, 2015 announced its financial results for the first quarter ended March 31, 2015. TrovaGene reported $0.13 million of revenue, an increase of 14.4% from $11 million reported last year in March.
Advaxis, Inc. (Advaxis) on May 05, 2015 announced that it has closed its public offering of 2.8 million shares of its common stock at a public offering price of $19.00 per share. The Company has received gross proceeds of $53.2 million, before deducting underwriting discounts and commissions and other estimated expenses, which the Company intends to use for fund research and development initiatives in connection with expanding product pipeline and for other general corporate purposes.
NewLink Genetics Corporation (NewLink) on May 5, 2015 announced its financial results for the first quarter ended March 31, 2015. The Company reported net income of $11.2 million or $0.35 per diluted share for the first quarter of 2015 compared to a net loss of $9.2 million or $0.33 per diluted share for the comparable period in 2014.
UniQure N.V. (UniQure) announced that it closed its follow on public offering of 3 million ordinary shares of its ordinary shares. The Company had priced the offering at $29.50 per ordinary share.
Spark Therapeutics Inc. (Spark) on May 6, 2015 announced its first quarter results, with revenue aggregating 2.3 million as compared to 0.02 million a year ago. Revenue for the quarter included $1.3 million of revenue associated with the Pfizer collaboration and recognition of $1.0 million non-refundable payment which the Company received after concluding discussions on a potential agreement with a pharmaceutical company.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article